Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N acetylcysteine amide - Nacuity Pharmaceuticals

Next Previous
Drug Profile

N acetylcysteine amide - Nacuity Pharmaceuticals

Alternative Names: AT-001 - Arctic Therapeutics; NACA - Nacuity Pharmaceuticals; NPI-001

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nacuity Pharmaceuticals
  • Class Eye disorder therapies; Neuroprotectants; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cystinosis; Usher syndromes
  • Phase I Retinitis pigmentosa

Most Recent Events

  • 12 Mar 2024 European Medicines Agency (EMA) grants approval for clinical trial for N-acetylcysteine-amide in Familial cerebral amyloid angiopathy in Iceland
  • 12 Mar 2024 Arctic Therapeutics plans a clinical trial in Familial cerebral amyloid angiopathy in Iceland
  • 29 Oct 2023 Phase-I/II clinical trials in Cystinosis (In children, In adolescents, In adults, In the elderly) in Australia (PO) (NCT05994534)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top